What is the latest market price of Tislelizumab in 2025?

Tislelizumab (Tislelizumab, trade name: BeiGene) is a humanized antiPD-1 monoclonal antibody drug independently developed by BeiGene. Since its approval for marketing in China in 2019, the drug has gradually occupied an important position in the tumor immunotherapy market due to its proven efficacy, wide coverage of indications and support from medical insurance policies. According to the latest market information in 2025, tislelizumab has been included in the national medical insurance directory, covering multiple indications including non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, and nasopharyngeal cancer.

In terms of price, the current sales specifications of tislelizumab in China are mainly 240mg/ tubes. The price of each tube varies according to the region and sales channels, ranging from RMB 1,300 yuan to 2,000 yuan. After reimbursement by medical insurance, patients' out-of-pocket expenses are significantly reduced. In some areas, the price after medical insurance can be as low as 300 per tube, which significantly reduces the burden of medication. Compared with imported PD-1 antibodies such as nivolumab (Opdivo) or pembrolizumab (Keytruda), tislelizumab has a clear advantage in price.

It is worth mentioning that tislelizumab not only continues to expand its market share in China, but was also approved by the U.S. FDA in 2023 for the treatment of esophageal squamous cell carcinoma, making it the first PD-1 drug independently developed by a Chinese company and approved in the United States. This internationalization achievement also adds confidence to its brand reputation and market prospects. From multiple perspectives such as medical insurance coverage, market performance and cost-effectiveness, tislelizumab has become one of the important representative drugs in the field of domestic tumor immunotherapy.

In short,2025 The market price of tislelizumab is generally close to the people, and its wide medical insurance coverage, coupled with its stable clinical efficacy and internationally recognized quality assurance, make it extremely competitive and clinically applicable in current tumor immunotherapy programs. Patients should have their indications evaluated by a professional doctor before use and purchase through regular channels.

Reference materials:https://www.drugs.com/donanemab.html